319 related articles for article (PubMed ID: 25070367)
1. A novel platform for engineering blood-brain barrier-crossing bispecific biologics.
Farrington GK; Caram-Salas N; Haqqani AS; Brunette E; Eldredge J; Pepinsky B; Antognetti G; Baumann E; Ding W; Garber E; Jiang S; Delaney C; Boileau E; Sisk WP; Stanimirovic DB
FASEB J; 2014 Nov; 28(11):4764-78. PubMed ID: 25070367
[TBL] [Abstract][Full Text] [Related]
2. Brain penetration, target engagement, and disposition of the blood-brain barrier-crossing bispecific antibody antagonist of metabotropic glutamate receptor type 1.
Webster CI; Caram-Salas N; Haqqani AS; Thom G; Brown L; Rennie K; Yogi A; Costain W; Brunette E; Stanimirovic DB
FASEB J; 2016 May; 30(5):1927-40. PubMed ID: 26839377
[TBL] [Abstract][Full Text] [Related]
3. Engineering and pharmacology of blood-brain barrier-permeable bispecific antibodies.
Stanimirovic D; Kemmerich K; Haqqani AS; Farrington GK
Adv Pharmacol; 2014; 71():301-35. PubMed ID: 25307221
[TBL] [Abstract][Full Text] [Related]
4. The blood-brain barrier transmigrating single domain antibody: mechanisms of transport and antigenic epitopes in human brain endothelial cells.
Abulrob A; Sprong H; Van Bergen en Henegouwen P; Stanimirovic D
J Neurochem; 2005 Nov; 95(4):1201-14. PubMed ID: 16271053
[TBL] [Abstract][Full Text] [Related]
5. Multiplexed evaluation of serum and CSF pharmacokinetics of brain-targeting single-domain antibodies using a NanoLC-SRM-ILIS method.
Haqqani AS; Caram-Salas N; Ding W; Brunette E; Delaney CE; Baumann E; Boileau E; Stanimirovic D
Mol Pharm; 2013 May; 10(5):1542-56. PubMed ID: 23150993
[TBL] [Abstract][Full Text] [Related]
6. Current strategies in antibody engineering: Fc engineering and pH-dependent antigen binding, bispecific antibodies and antibody drug conjugates.
Vincent KJ; Zurini M
Biotechnol J; 2012 Dec; 7(12):1444-50. PubMed ID: 23125076
[TBL] [Abstract][Full Text] [Related]
7. Brain uptake of multivalent and multi-specific DVD-Ig proteins after systemic administration.
Karaoglu Hanzatian D; Schwartz A; Gizatullin F; Erickson J; Deng K; Villanueva R; Stedman C; Harris C; Ghayur T; Goodearl A
MAbs; 2018 Jul; 10(5):765-777. PubMed ID: 29771629
[TBL] [Abstract][Full Text] [Related]
8. Isolation of blood-brain barrier-crossing antibodies from a phage display library by competitive elution and their ability to penetrate the central nervous system.
Thom G; Hatcher J; Hearn A; Paterson J; Rodrigo N; Beljean A; Gurrell I; Webster C
MAbs; 2018; 10(2):304-314. PubMed ID: 29182455
[TBL] [Abstract][Full Text] [Related]
9. A new generation of neurobiological drugs engineered to overcome the challenges of brain drug delivery.
Boado RJ
Drug News Perspect; 2008 Nov; 21(9):489-503. PubMed ID: 19180267
[TBL] [Abstract][Full Text] [Related]
10. SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies.
Davis JH; Aperlo C; Li Y; Kurosawa E; Lan Y; Lo KM; Huston JS
Protein Eng Des Sel; 2010 Apr; 23(4):195-202. PubMed ID: 20299542
[TBL] [Abstract][Full Text] [Related]
11. Selection of phage-displayed llama single-domain antibodies that transmigrate across human blood-brain barrier endothelium.
Muruganandam A; Tanha J; Narang S; Stanimirovic D
FASEB J; 2002 Feb; 16(2):240-2. PubMed ID: 11772942
[TBL] [Abstract][Full Text] [Related]
12. Re-engineering therapeutic antibodies for Alzheimer's disease as blood-brain barrier penetrating bi-specific antibodies.
Pardridge WM
Expert Opin Biol Ther; 2016 Dec; 16(12):1455-1468. PubMed ID: 27572805
[TBL] [Abstract][Full Text] [Related]
13. Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood-Brain Barrier.
Stanimirovic DB; Sandhu JK; Costain WJ
BioDrugs; 2018 Dec; 32(6):547-559. PubMed ID: 30306341
[TBL] [Abstract][Full Text] [Related]
14. Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier.
Haqqani AS; Delaney CE; Brunette E; Baumann E; Farrington GK; Sisk W; Eldredge J; Ding W; Tremblay TL; Stanimirovic DB
J Cereb Blood Flow Metab; 2018 Apr; 38(4):727-740. PubMed ID: 29140158
[TBL] [Abstract][Full Text] [Related]
15. Generating bispecific human IgG1 and IgG2 antibodies from any antibody pair.
Strop P; Ho WH; Boustany LM; Abdiche YN; Lindquist KC; Farias SE; Rickert M; Appah CT; Pascua E; Radcliffe T; Sutton J; Chaparro-Riggers J; Chen W; Casas MG; Chin SM; Wong OK; Liu SH; Vergara G; Shelton D; Rajpal A; Pons J
J Mol Biol; 2012 Jul; 420(3):204-19. PubMed ID: 22543237
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic assessment of SEED: a new engineered antibody platform designed to generate mono- and bispecific antibodies.
Muda M; Gross AW; Dawson JP; He C; Kurosawa E; Schweickhardt R; Dugas M; Soloviev M; Bernhardt A; Fischer D; Wesolowski JS; Kelton C; Neuteboom B; Hock B
Protein Eng Des Sel; 2011 May; 24(5):447-54. PubMed ID: 21498564
[TBL] [Abstract][Full Text] [Related]
17. Engineering of stable bispecific antibodies targeting IL-17A and IL-23.
Mabry R; Lewis KE; Moore M; McKernan PA; Bukowski TR; Bontadelli K; Brender T; Okada S; Lum K; West J; Kuijper JL; Ardourel D; Franke S; Lockwood L; Vu T; Frank A; Appleby MW; Wolf A; Reardon B; Hamacher NB; Stevens B; Lewis P; Lewis KB; Gilbertson DG; Lantry M; Julien SH; Ostrander C; Chan C; Byrnes-Blake K; Brody J; Presnell S; Meengs B; Levin SD; Snavely M
Protein Eng Des Sel; 2010 Mar; 23(3):115-27. PubMed ID: 20022918
[TBL] [Abstract][Full Text] [Related]
18. Genetic engineering, expression, and activity of a fusion protein of a human neurotrophin and a molecular Trojan horse for delivery across the human blood-brain barrier.
Boado RJ; Zhang Y; Zhang Y; Pardridge WM
Biotechnol Bioeng; 2007 Aug; 97(6):1376-86. PubMed ID: 17286273
[TBL] [Abstract][Full Text] [Related]
19. Reengineering biopharmaceuticals for targeted delivery across the blood-brain barrier.
Pardridge WM; Boado RJ
Methods Enzymol; 2012; 503():269-92. PubMed ID: 22230573
[TBL] [Abstract][Full Text] [Related]
20. Boosting brain uptake of a therapeutic antibody by reducing its affinity for a transcytosis target.
Yu YJ; Zhang Y; Kenrick M; Hoyte K; Luk W; Lu Y; Atwal J; Elliott JM; Prabhu S; Watts RJ; Dennis MS
Sci Transl Med; 2011 May; 3(84):84ra44. PubMed ID: 21613623
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
